Navigation Links
Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
Date:7/22/2009

CHICAGO, July 22 /PRNewswire-FirstCall/ -- Research presented at the American Association for Clinical Chemistry (AACC) annual meeting today indicates that monitoring cardiac transplant patients with the Urine NGAL assay on Abbott's ARCHITECT immunoassay analyzer may help clinicians to monitor cyclosporine-induced toxicity and adjust doses of cyclosporine drugs to prevent possible irreversible kidney damage.

In a scientific poster presented at AACC today by researchers at the University of Toronto, eleven heart transplant patients were treated with anti-rejection drug combinations and monitored with the Urine NGAL assay within twelve hours of administration. The study concluded that Urine NGAL monitoring may be able to assist in the detection of chronic cyclosporine-induced toxicity in the kidneys following heart transplant procedures.

Abbott is currently developing an assay to measure NGAL (neutrophil gelatinase-associated lipocalin) concentrations in urine for use on the company's flagship automated laboratory instrument, the ARCHITECT system. Abbott has rights to commercialize Urine NGAL for renal diagnostic applications and is expected to introduce the product in Europe in late 2009. The assay is not available in the United States. NGAL is a small, robust protein produced by the kidney tubules and appears in urine just two-to-four hours following acute kidney injury (AKI), up to 46 hours sooner than current test methods.

"Nephrologists and cardiologists are excited about the potential of Urine NGAL to detect the potential for kidney failure following cardio-thoracic surgeries," said Sudarshan Hebbar, M.D., medical director, Abbott Diagnostics.

About Abbott's Diagnostics Businesses

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs. The history of Abbott is filled with examples of first-of-a-kind diagnostic products and significant technological and research advancements.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

ARCHITECT is a trademark of Abbott Laboratories.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
2. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
5. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
6. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
7. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
8. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393
9. U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia
10. Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkins Lymphoma
11. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... and Migraine Therapeutics Summit ( http://www.paintherapeuticsummit.com ) is coming to San Diego, CA ... attend this conference to learn about the latest advances in the treatment of ...
(Date:4/27/2017)... ... April 27, 2017 , ... The Council for Agricultural Science ... Jayson Lusk, a consummate communicator who promotes agricultural science and technology in the ... he explains how innovation and growth in agriculture are critical for food security ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... FDA’s GMP expectations for phase I clinical trials comes to Tampa, San Francisco ... biotechnology and pharma professionals representing FDA regulated organizations such as Pfizer Inc., Teva ...
(Date:4/26/2017)...  Genisphere LLC, provider of the 3DNA ® ... and sponsored research agreement with the University of ... overall goal of the partnership is to study ... and formulations after in vivo administration. ... as well as inflammatory responses, demonstrating various methods ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):